Clinical Trial Update: Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the efficacy and safety of an 8-week fixed-dose combination of ledipasvir/sofosbuvir in adults with chronic genotype 1 Hepatitis C co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• HARVONI (Ledipasvir and Sofosbuvir)

Snippet

Sponsor: Peter J. Ruane, M.D., Inc. | Conditions: Treatment of Hepatitis C | Phase 2 | Status: COMPLETED